Literature DB >> 7909159

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

Y Noguchi1, Y T Chen, L J Old.   

Abstract

The T-cell response to mutated and normal p53 products of BALB/c-derived Meth A sarcoma was analyzed. Meth A p53 is known to have three missense point mutations in codons 132, 168, and 234, and 24 peptides containing wild-type or mutated sequences at the three mutation sites were constructed. Spleen cells from BALB/c or (BALB/c x C57BL/6)F1 mice immunized with p53 peptides were sensitized in vitro with the corresponding peptides. Because Meth A is resistant to cytotoxic T cells, the sensitive P1-HTR cell line, which expresses a low level of p53 lacking the Meth A p53 mutations, was chosen as a target, either pulse-labeled with p53 peptides or transfected with plasmids containing coding sequences from Meth A p53. One peptide, a nonamer containing the codon 234 mutation (234CM), induced CD8+ cytotoxic T cells that lysed 234CM-pulsed P1-HTR cells in an H-2Kd-restricted fashion. P1-HTR cells pulsed with the corresponding wild-type peptide were only weakly lysed by 234CM-reactive cytotoxic T cells. P1-HTR cells pulsed with other wild-type or mutated p53 peptides were not lysed by 234CM-reactive cytotoxic T cells, nor could these peptides, including 234CW (the wild-type counterpart to 234CM), elicit cytotoxic cells. P1-HTR cells transfected with plasmids coding for the 234CM sequence and expressing high p53 levels were weakly lysed by 234CM-reactive cytotoxic T cells. However, lysis of one of the transfectants was significantly increased by pretreatment with interferon gamma. A proliferative response of CD4+ T cells was elicited by immunization with 234CM and 234CW, but not with other p53-related peptides. The specificity of 234CM-induced CD4+ T cells for 234-region peptides was broader than the reactivity of 234CM-reactive cytotoxic T cells. Mice immunized with 234CM in incomplete Freund's adjuvant showed heightened resistance to Meth A challenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909159      PMCID: PMC43537          DOI: 10.1073/pnas.91.8.3171

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Selection of highly transfectable variant from mouse mastocytoma P815.

Authors:  A Van Pel; E De Plaen; T Boon
Journal:  Somat Cell Mol Genet       Date:  1985-09

3.  Monoclonal antibodies specific for simian virus 40 tumor antigens.

Authors:  E Harlow; L V Crawford; D C Pim; N M Williamson
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

4.  Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex.

Authors:  K Ozato; T H Hansen; D H Sachs
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

5.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Authors:  D P Dialynas; Z S Quan; K A Wall; A Pierres; J Quintáns; M R Loken; M Pierres; F W Fitch
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

6.  Monoclonal antibodies to mouse major histocompatibility complex antigens.

Authors:  K Ozato; N M Mayer; D H Sachs
Journal:  Transplantation       Date:  1982-09       Impact factor: 4.939

7.  Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

Authors:  D I Linzer; A J Levine
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

8.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

Authors:  M Yanuck; D P Carbone; C D Pendleton; T Tsukui; S F Winter; J D Minna; J A Berzofsky
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

9.  A mouse tumor-specific transplantation antigen is a heat shock-related protein.

Authors:  S J Ullrich; E A Robinson; L W Law; M Willingham; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.

Authors:  E Nakayama; A Uenaka
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

View more
  31 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

Review 3.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Authors:  Parisa Malekzadeh; Anna Pasetto; Paul F Robbins; Maria R Parkhurst; Biman C Paria; Li Jia; Jared J Gartner; Victoria Hill; Zhiya Yu; Nicholas P Restifo; Abraham Sachs; Eric Tran; Winifred Lo; Robert Pt Somerville; Steven A Rosenberg; Drew C Deniger
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

5.  Down-regulated expression of monocyte/macrophage major histocompatibility complex receptors in human and mouse monocytes by expression of their ligands.

Authors:  H Yamana; J Tashiro-Yamaji; M Hayashi; S Maeda; T Shimizu; N Tanigawa; K Uchiyama; T Kubota; R Yoshida
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

6.  Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.

Authors:  H Ikeda; N Ohta; K Furukawa; H Miyazaki; L Wang; K Kuribayashi; L J Old; H Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.

Authors:  H Saito; K Kitagawa; T Yoneda; Y Fukui; M Fujsawa; D Bautista; T Shirakawa
Journal:  Cancer Gene Ther       Date:  2017-06-16       Impact factor: 5.987

8.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

9.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Authors:  J Roth; D Dittmer; D Rea; J Tartaglia; E Paoletti; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.

Authors:  Y Noguchi; E C Richards; Y T Chen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.